Trevor Allred
Stock Analyst at Oppenheimer
(4.68)
# 170
Out of 5,133 analysts
15
Total ratings
86.67%
Success rate
40.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Initiates: Outperform | $75 | $22.57 | +232.30% | 1 | Jan 7, 2026 | |
| DSGN Design Therapeutics | Initiates: Outperform | $18 | $9.58 | +87.89% | 1 | Jan 7, 2026 | |
| TBPH Theravance Biopharma | Initiates: Outperform | $27 | $20.33 | +32.81% | 1 | Dec 3, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $250 → $275 | $188.78 | +45.67% | 8 | Nov 7, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $80 | $36.31 | +120.32% | 2 | Sep 23, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $85 | $103.54 | -17.91% | 1 | Sep 9, 2025 | |
| INVA Innoviva | Initiates: Outperform | $35 | $19.51 | +79.40% | 1 | Aug 11, 2025 |
Legend Biotech
Jan 7, 2026
Initiates: Outperform
Price Target: $75
Current: $22.57
Upside: +232.30%
Design Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $18
Current: $9.58
Upside: +87.89%
Theravance Biopharma
Dec 3, 2025
Initiates: Outperform
Price Target: $27
Current: $20.33
Upside: +32.81%
Ligand Pharmaceuticals
Nov 7, 2025
Maintains: Outperform
Price Target: $250 → $275
Current: $188.78
Upside: +45.67%
MBX Biosciences
Sep 23, 2025
Maintains: Outperform
Price Target: $38 → $80
Current: $36.31
Upside: +120.32%
Palvella Therapeutics
Sep 9, 2025
Initiates: Outperform
Price Target: $85
Current: $103.54
Upside: -17.91%
Innoviva
Aug 11, 2025
Initiates: Outperform
Price Target: $35
Current: $19.51
Upside: +79.40%